Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Cisco Systems Inc (CSCO) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Cisco Systems IncTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Cisco Systems Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.1 (market cap $29.60B), while Cisco Systems Inc trades at $122.97 (market cap $474.67B). The key difference: Cisco Systems Inc is far larger — about 16× Alnylam Pharmaceuticals, Inc.'s market cap, and Cisco Systems Inc pays a 1.4% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.

ALNYCSCO
Market Cap
$29.60B$474.67B
Sector
HealthTechnology
52-Week High
$491.22$130.00
52-Week Low
$205.48$66.20
Enterprise Value
$27.56B$489.33B
Volume
22,887,319
Dividend Yield
1.4%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.

The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.

Cisco Systems Inc

Cisco Systems (CSCO) trades at $122.57, up 0.94% today, near its recent highs driven by strong AI cybersecurity momentum. The stock shows bullish technical signals with moving averages supporting the uptrend, while RSI levels indicate potential overbought conditions. Fundamentally, CSCO reported revenue of $56.65B in 2025 with a net income margin of 19.69%, and has beaten EPS estimates for three consecutive quarters. Recent news highlights partnerships and product launches in AI security, fueling investor optimism.

CSCO's outlook is positive with a consensus price target of $133.25, implying ~9% upside, supported by 52% analyst buy ratings. Key opportunities include growth in AI-driven networking and security demand, but risks involve high valuation multiples (P/E 40.14) and competitive pressures in the tech sector. Investors should weigh strong cash flow generation against execution risks in a dynamic market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Cisco Systems Inc

Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.

Read more on CSCO